Neurochem Provides Information on Cash Position

LAVAL, QC, August 28, 2007 /PRNewswire-FirstCall/ - Following the issuance of a press release on August 26, 2007, announcing results from the tramiprosate (Alzhemed) North American Phase III clinical trial and the subsequent conference call on August 27, 2007, Neurochem Inc. wishes to re-iterate that while it does not provide guidance regarding financial matters, in light of circumstances surrounding the announcement and subsequent call, based on the unaudited financial statements of the Company as at July 31, 2007, the cash position was approximately US$80 million.

The Company believes that while its cash reserves should support current operations for 15 to 18 months, the recommendations of the newly established Special Advisory Board for tramiprosate (Alzhemed) and other upcoming milestone events make it impossible to predict with certainty the Company's cash requirements at any point in time.

About Neurochem

Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. Eprodisate (KIACTA) is currently being developed for the treatment of Amyloid A amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration, the European Medicines Agency and Swissmedic. Tramiprosate (Alzhemed), for the treatment of Alzheimer's disease, has been the subject of a completed Phase III clinical trial in North America and is currently being studied in a Phase III clinical trial in Europe, while tramiprosate (CEREBRIL), for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy, has been studied in a completed Phase IIa clinical trial.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 (877) 680-4500 or visit the Web site at www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

lhebert@neurochem.com

CONTACT: Lise Hebert, Ph.D., Vice President, Corporate Communications,(450) 680-4572, lhebert@neurochem.com

Ticker Symbol: (Toronto:NRM.),(NASDAQ-NMS:NRMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: August 2007

View comments

Hide
(web5)